Hanmi Pharmaceutical is developing in the areas of anti-cancer, obesity, diabetes, and rare diseases. About Luye Pharma Group Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. Skin is the amazing layer of life that protects us from the elements and connects us to the world. Luye Pharma has reached a high level international standard in novel drug delivery technologies such as microspheres, liposomes and transdermal drug delivery systems, with the company making active efforts to develop biological antibodies, cell and gene therapies. One of China's leading pharmaceutical companies, Luye Pharma (02186. Luye Pharma focuses on developing, producing, marketing and selling innovative pharmaceutical products in four of the largest and fastest growing therapeutic areas — oncology, cardiovascular, metabolism and the central nervous system, covering the main global pharmaceutical markets, including China, the U.S. Europe and Japan. Luye Pharma's strategic approach in this treatment area will set the tone for the company's next stage of business growth. About. As part of the Luye Life Sciences Group, we are an expert and reliable partner to the global pharmaceutical industry. robust pipeline of 40+ drug candidates in ... With global R&D, global manufacturing, and global market as its three strategic priorities, Luye Pharma is committed to providing customers with high-quality medicines and professional services. Over the past 22 years, this group of pharmaceutical companies has taken on truly international proportions. If the product you need is not already part of our development program, we can arrange a contract development model that suits your needs. OT-702 complements and strengthens the company's posterior eye product line. Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. In addition to the newly approved Rykindo®, Luye Pharma has more than eight innovative pipeline products in various stages of development, all under the innovative microsphere technology platform and targeting major therapeutic areas, such as oncology and central nervous system, to … Global R&D 2 Passionate for Life . Boan Biotech’s Nivolumab Injection LY01015 to Start Clinical Trials in China, As the first applied biosimilar to Opdivo® according to Registration ... Luye Pharma Group announced that the clinical trial application for LY01015 (Nivolumab Injection) developed by the Group's subsidiary Boan Biotech, has been accepted by the Center for Drug Evaluation of the China National Medical Products ... Luye Pharma and Towa Pharmaceutical Enter Strategic Collaboration to Develop and Commercialize Rivastigmine Multi-Day Transdermal Patch in Japan. Administered once a day to the body through the skin, the drug is ... Upholding the philosophy of “Employee Development”, Luye Pharma regards employees as the most valuable resources of the company, Adequate Career Opportunities for Female Professionals, VP of Strategy & Business Development, Luye Pharma, Luye Pharma Is like an International Family, APAC Commercial Director, Luye Pharma (International), To Learn and Grow through Problem Discovery and Resolution, Director of Analytical Research and Development, R&D Center, Luye Pharma, Director of Engineering Department II, Shandong Luye, Attracted by Luye's Development Strategy and Innovation Mechanism, VP of Biologics technology Transfer and Commercial Manufacturing (including CMO), Luye Pharma, Unveiling the Legend of Innovation: The Perseverance of Our R&D Staff. Luye Pharma AG Services: R&D, licensing, supply chain, production, packaging and quality assurance. Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. In its core operations, it is now a global market leader. Calculate route. Located in China, the United States and Europe, Long-acting and Extended Release Technology, Liposome and Targeted Drug Delivery Technology. At SUN Dermatology, we have more than 30 years of experience in developing innovative dermatologic treatments, and we care to make a difference—in the lives of patients and those who care for them. We are positioned to expand our clinical development programs to target broader conditions with these novel treatments in the years ahead. Luye Medical Group establishes mental health division in China. 2 R & D Learn more. Luye Pharma has reached a high level international standard in novel drug delivery technologies such as microspheres, liposomes and transdermal drug delivery systems, with the company making active efforts to develop biological antibodies, cell and gene therapies. Address: Luye Pharma AG Am Windfeld 35 83714 Miesbach Germany. Luye Pharma has embarked on a number of license-in agreements and collaborations in the first half of 2019, based on the company's strategy of internationalization, which supports product pipeline development and improvements to commercial capability. Global R&D, global manufacturing, and the global sale of innovative medications are the company’s three main strategic priorities. 3 R&D centers Located in China, the United States and Europe Stay up to date with the latest news on Timber Pharmaceuticals (TMBR). The company has established R&D centers in China, the U.S. and the EU, with a robust pipeline of more than 40 drug candidates in … 29 awards on national and provincial levels, including a 2nd prize of National Technology Invention Award, a 2nd prize of National Science & Technology Progress Award, 1 first prize of Science & Technology Progress Award presented by Chinese Pharmaceutical Association, Undertaking 60+ national-level key research projects, Several papers published in international peer-reviewed journals, Laboratory of Long-acting and Targeting Drug Delivery System, Cooperation Base for International Science & Technology, Industrialization Base of National 863 Program, State Intellectual Property Exemplary Company, The 1st wave of national enterprises to export IP rights. Our CEO, David K. Lee, recently spoke with Luke Timmerman on his podcast, The Long Run, discussing how his upbringing influenced his desire to impact patient's lives directly, and how Servier is a different kind of pharmaceutical company. Luye Pharma Group (02186.HK), a member of Luye Life Sciences Group, is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. Phone: +49 (8025) 2867-0 Fax: +49 (8025) 2867-28 Email: info luyepharma eu 2019 Collaborated with AstraZeneca to promote high-quality TCM product- Xuezhikang to China and global markets Strategic Pipeline. We are pleased to enter into the R&D and commercial cooperation of OT-702 with Luye Pharma. It will also be used to form a McAb + fusion protein pipeline combination with OT-701 (a similar drug of raizumab) to fully cover anti-VEGF drugs for macular lesions. About Luye Pharma Group. The proprietary LNP platform adds value to the pipeline by enabling tissue and organ specific delivery; Developed next-generation cell therapy technologies engineered to target neo-tumor antigens and accomplish other therapeutic functions. Investor Relations. Luye Pharma Group (02186.HK), a member of Luye Life Sciences Group, is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has a robust pipeline of over 30 drug candidates in China and more than 10 drug candidates overseas. The company has established R&D centers in China , the U.S. and Europe , with a robust pipeline of nearly 40 drug candidates in China and more than 10 drug candidates overseas. The financial report shows that the company enjoyed strong LY03010 is one of the key investigational drugs in the company's Central Nervous System (CNS) pipeline and is indicated for the treatment of schizophrenia and schizoaffective disorders. R&D Pipeline. ... the U.S. and Europe, with a robust pipeline of over 30 drug candidates in China and more than 10 drug candidates in other international markets. The following Luye Pharma products are currently available for licensing. Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. Luye Pharma Group announced that its subsidiary Luye Pharma Switzerland AG has entered into an agreement with Towa Pharmaceutical Co., Ltd. (Towa), the terms of which grant Towa exclusive rights to the development and commercialization of ... Luye Pharma Group today announced that Shandong Boan Biotechnology Co. Ltd. (Boan Biotech) has completed the first patient dosing in the phase Ⅲ clinical trial for LY09004 in China. HK), released its annual results on March 26, 2018 . Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. R&D: Luye Pharma has achieved breakthroughs around the world in pipeline building, putting into place a strong biological antibody pipeline. Set up Luye Pharma Ltd UK Set up S&M field force in GCC Operations Agreement to promotion 2017 Set-up Luye Pharma European HQ 2013 Set up US Business and R&D 2019 2019 first NDA submission for Rykindo ® Licensing Robust pipeline with 40 products Focus on CNS and Oncology Launch overseas production Global supply chain management system Luye Pharma's strategic approach in this treatment area will set the tone for the company's next stage of business growth. In the rapidly growing market for transdermal patches, we specialize in the development and manufacture of new dosage forms for proven active substances. Luye Pharma Group, a member of Luye Life Sciences Group, is an international pharmaceutical company with a focus on targeting central nervous system (CNS), oncology and other therapeutic areas. Luye Pharma Acquires Boan with Strategic Plans in Biopharmaceuticals Further Strengthening Product Pipeline and Accelerating Global Business Growth December 1, 2019, Luye Pharma Group has announced the acquisition of Shandong Boan Biological Technology Co. Ltd. (Boan), accelerating its global strategy in the field of biopharmaceuticals. After the acquisition, Luye Pharma will possess a series of assets from Boan comprising the entire product pipeline, antibody screening platform, antibody manufacturing platform and related intellectual property, among others, establishing a complete industry chain covering R&D, manufacturing and commercialization in the biopharmaceutical arena. If you are interested in other products, please contact us. Both harbor significant potential to address a wide spectrum of diseases; Delivery is a critical enabling element in nucleic and gene therapy. The company is forward looking, with strategic development of innovative new compounds and antibodies, gene & cell therapies and smart formulations. R&D: Luye Pharma has achieved breakthroughs around the world in pipeline building, putting into place a strong biological antibody pipeline. The company currently has a number of new drugs and new Improve cancer treatment by providing a personalized therapy option; The Laboratory of Long-acting and Targeting Drug Delivery System, focusing on the research of: Long-acting drug delivery system and drug release technology, Targeting drug delivery system and drug release technology, High-end carrier materials for long-acting and targeting drug delivery, located in China, the United States and Europe, Undertaking 60+ national-level key research projects, Post-doctorate Scientific Research Work Station. The hero of the global First-in Class is Hanmi Pharmaceutical. Robust Pipeline Luye Pharma is a global cutting edge company in terms of research into new drug delivery technologies, such as microspheres, liposomes and transdermal drug delivery systems. PHM-TPD platform based on targeted protein degradation; key procedure establishment for targets discovery, drug design and synthesis, biological screening and evaluation; Human Antibody Transgenic Mouse and Phage Display Technology: Significant improvement of efficiency and speed in antibody development, effective screening of antibody candidates; High affinity binding to tumor targets (better efficacy), low affinity binding to T-cells (lower toxicity), a wider therapeutic window; Efficient screening of high-quality antibodies for ADC（Antibody Drug Conjugate); Efficient screening, evaluation and manufacturing process development have ensured the druggability of nanobodies; Research and development of novel therapies including AAV-based gene therapy and nucleic acid therapy (mRNA and Oligo). BASEL, Switzerland, Feb. 18, 2021 /PRNewswire/ -- Luye Pharma Group announced that its subsidiary Luye Pharma Switzerland AG has entered into an … The Luye Pharma Group was listed on the Hong Kong Stock Exchange in mid-2014. The company has a number of pipeline products in the CNS therapeutic area being concurrently developed for the Chinese and overseas markets. About Luye Pharma Group. Novel non viral vector technology to enhance manufacturing efficiency. Focus. Luye Pharma: A Healthy Thirty Percent Annual Growth Rate, with Competitive Product Pipelines across Different Therapeutic Areas Published: Mar 29, 2018 HONG KONG, March 29, 2018 /PRNewswire/ -- One of China's leading pharmaceutical companies, Luye Pharma (02186. Long-acting and extended release technology. The company has a robust pipeline of over 40 drug candidates in China and more than 10 drug candidates in other international markets. As a key area for research and ... On January 31, 2021, Luye Pharma Group announced a subscription agreement with Hillhouse NEV, a company of Hillhouse Capital Group, involving HK$1.25 billion of investment from Hillhouse in exchange for issuing ... Luye Pharma Group today held a press conference to announce the launch of its Rivastigmine Transdermal Patch (Brand Name: 金斯明®) in China. Learn more. Liposome and targeted drug delivery technology. ... the U.S. and Europe, with a robust pipeline of more than 40 drug candidates in China and more than 10 drug candidates overseas.